Non-invasive Heart Bypass I would like to inform people of a therapy that is in over 600 hospitals & clinic's throughout the USA successfully treating 1000's of people, and is now being introduced into hospitals & clinic's in Europe and around the world. For more information on the therapy for treating people with heart problems such as Angina Pectoris, Congestive Heart Failure and more please visit the web sites mentioned below.
Also : Patients with CAD whos angina pectoris is refractory to medical therapy Patients who are inoperable or at a higher than normal risk of complications Patients whose coronary anatomy is not readily accessible to such procedures Patients with co-morbidities that create excessive risk ANNOUNCEMENT!EECP NEW FDA CLEARED INDICATION FOR CHF PATIENTS
CURRENT INDICATIONS: CONGESTIVE HEART FAILURE, STABLE AND UNSTABLE ANGINA, MYCARDIAL INFARCTION AND CARDIOGENIC SHOCK
EECP CLINICAL BENEFITS (Demonstrated in over 40 journal articles, 70 abstracts as well as an International EECP Patient Registry of over 5,000 patients)
- REDUCE ANGINA CLASS 1-2 LEVELS FOR 24-36 MONTHS
- INCREASED TIME TO ST SEGMENT DEPRESSION
- INCREASE VO2 MAX
- DECREASE BNP & ENDOTHELIN
- INCREASE NITRIC OXIDE LEVELS
- INCREASE VEGF AND PROMOTE RECRUITMENT OF COLLATERALS
- IMPROVE LV FUNCTION
- IMPROVE EJECTION FRACTION
- DECREASE LV END DIASTOLIC PRESSURE
- DECREASE SVR & LOWER BLOOD PRESSURE
- REDUCTION IN NITRO USE & ANGINAL EPISODES
- INCREASE EXERCISE TOLERANCE
EECP is Virtually Risk Free and does not affect other invasive treatment options
EECP can be adjunctive to PTCA or CABG
HEMODYNAMIC ADVANTAGES
- Increases Venous Return
- Increases Cardiac Output
- Reduces Systolic Pressure (Ventricular Unloading)
- Increases Myocardial Perfusion
- Decreases Oxygen Demand
- Increases Oxygen Utilization